![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 31/55 | |
A61K 31/436 | |||
A61K 38/13 | |||
A61K 31/439 | |||
A61K 31/4427 | |||
A61K 31/4985 | |||
A61K 31/4439 | |||
A61K 31/4995 | |||
A61K 45/06 | |||
A61P 27/02 | |||
A61P 11/02 | |||
A61P 25/02 | |||
A61K 9/00 | |||
A61K 9/08 |
(11) | Number of the document | 3209295 |
(13) | Kind of document | T |
(96) | European patent application number | 15852340.7 |
Date of filing the European patent application | 2015-10-19 | |
(97) | Date of publication of the European application | 2017-08-30 |
(45) | Date of publication and mention of the grant of the patent | 2020-12-09 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2015/056273 |
Date | 2015-10-19 |
(87) | Number | WO 2016/064759 |
Date | 2016-04-28 |
(30) | Number | Date | Country code |
201462066280 P | 2014-10-20 | US | |
201562100844 P | 2015-01-07 | US |
(72) |
ACKERMANN, Douglas Michael, Jr., US
LOUDIN, James, US
MANDELL, Kenneth J., US
|
(73) |
Oyster Point Pharma, Inc.,
202 Carnegie Center, Suite 109, Princeton, New Jersey 08540,
US
|
(54) | METHODS OF TREATING OCULAR CONDITIONS |
METHODS OF TREATING OCULAR CONDITIONS |